Suven Life Sciences Ltd (Suven) has received four product patents – one each from Australia & Hong Kong, and two from Japan –for the new chemical entity (NCE), which can be used for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2030, said the company.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 19 granted patents from Australia, 14 from Japan and 15 from Hong Kong. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 19 granted patents from Australia, 14 from Japan and 15 from Hong Kong. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for major depressive disorder with high unmet medical need with huge market potential globally,” said Venkat Jasti, CEO of Suven.